Dicer­na and Boehringer part­ner on RNAi treat­ment for NASH

Phar­ma gi­ant Boehringer In­gel­heim In­ter­na­tion­al is part­ner­ing with Dicer­na Phar­ma­ceu­ti­cals $DR­NA on a re­search and li­cens­ing deal to ad­vance treat­ments for chron­ic liv­er dis­eases.

Dicer­na gets $10 mil­lion in an up­front pay­ment, and could re­ceive up to an ad­di­tion­al $191 mil­lion in po­ten­tial mile­stone pay­ments and R&D re­im­burse­ments.

The duo will ini­tial­ly fo­cus on non­al­co­holic steato­hep­ati­tis (NASH), al­so known as non­al­co­holic fat­ty liv­er dis­ease, which has been a bea­con for a slew of bio­phar­ma com­pa­nies out to con­quer a fast-grow­ing ail­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.